AI summary by TwinMind
Insulin Prices Have Skyrocketed. Here’s How California Aims to Change That. | WSJ
The Wall Street Journal
7m 54s
California's Insulin Manufacturing Initiative
- Governor Gavin Newsom announced first-in-nation plan for California to manufacture its own insulin
- State allocating $100 million in budget:
- $50 million to develop low-cost insulin
- $50 million to establish in-state manufacturing facility
- State involvement eliminates profit motive, enabling very low-cost production
- Governor's office projects cost reduction from $300-500/month to at minimum half that amount
- Full details not announced including availability timeline and exact pricing
Current Insulin Market Crisis
- Americans pay ~8x more for insulin than rest of developed world
- 2020 Medicare Part D average out-of-pocket: $54 per prescription
- Essential medication for 7.4 million diabetic Americans (~2% of US population)
- Discovered 1921, life-saving drug for Type 1 diabetes which was previously often fatal
Market Structure Problems
- Three manufacturers control almost 100% of US insulin supply
- Complex manufacturing process with less established regulatory pathway for biosimilar competition
- Limited competition due to regulatory barriers
- All supply chain entities are for-profit with fiduciary responsibility to shareholders, not patients
Pricing Complexity and Middlemen Issues
- List price vs. net price discrepancy:
- 2019 Sanofi example: average list price $361, net price $62
- Pharmacy Benefit Managers (PBMs) identified as contributing factor in 2021 Senate investigation
- PBMs negotiate between manufacturers, insurance companies, and pharmacies
- Manufacturers pay discounts, rebates, coupons, fees back through distribution system
- Net price = list price minus all discounts/rebates/fees
- Sanofi claims net insulin prices fallen for seven consecutive years
Alternative Models Emerging
Mark Cuban Cost Plus Drug Company
- Launched earlier in 2022
- Online store selling hundreds of low-cost generic medications
- Model undercuts traditional supply chain by selling directly to consumers
- Eliminates PBMs from process
Civica Rx Non-Profit Model
- Established by hospitals and philanthropic groups
- Healthcare utility model with membership structure
- Hospital systems partner to purchase generic drugs
- Launched September 2018, now producing 64 generic drugs
- Building 140,000 sq ft manufacturing facility in Petersburg, Virginia
- Plans insulin production by early 2024
- Pricing commitment: max $30/vial, $55 for 5-pen cartridges
- Will manufacture three generic insulins in vials and pre-filled pens
- Facility capable of 100% vial capacity for entire country
- Only enters markets with distortion/failure, avoids well-functioning markets
Federal Policy Response
- President Biden signed prescription drug price legislation August 16th
- Medicare insulin costs capped at $35/month starting next year
- Biden noted 18-month anticipation of this action
Industry Responses
- Novo Nordisk: developing programs to ensure diabetes patients get needed insulin
- Eli Lilly: committed to affordability, advocates passing rebates directly to patients and limiting out-of-pocket costs
- Sanofi: emphasizes net price reductions over seven years, notes PBM rebate demands ingrained in healthcare system
Market Impact Projections
- Introduction of low-cost alternatives would force established players to accept lower profit margins
- California's non-profit approach could significantly disrupt current pricing structure
